血清YKL-40水平与肺癌合并COPD患者预后不良的关系

The correlation between serum level of YKL-40 and poor prognosis in patients with lung cancer and COPD

目的探讨血清YKL-40水平与肺癌及其合并症患者预后之间的联系。方法研究共纳入100例肺癌患者,30名健康志愿者作为对照组。记录两组人口学特征,根据合并症分组进行分析,酶联免疫吸附测定(ELISA)血清YKL-40水平。结果肺癌患者血清YKL-40水平显著高于对照组(P<0.001),而其水平与临床分期、肿瘤大小、有无淋巴结受累和远处转移无关。YKL-40水平高于临界值(133 ng/mL),患者的存活时间显著缩短(P<0.05)。YKL-40水平高于临界值合并慢性阻塞性肺疾病(COPD)的患者生存期更短(P<0.05)。结论 YKL-40水平可作为肺癌诊断的指标,与肺癌合并COPD患者的预后不良有关。

Objective To investigate the correlation between YKL-40 level in serum and the prognosis of patients with lung cancer and its comorbidities. Methods A total of 100 lung cancer patients and 30 healthy volunteers(control group) were included. Demographic characteristics were recorded. YKL-40 level in serum was determined by enzyme-linked immunosorbent assay (ELISA). Results YKL-40 in serum of lung cancer patients was significantly higher than that in the control group(P<0.001), which was not correlated with clinical stage, tumor size, lymph node involvement or distant metastasis. When YKL-40 level was higher than the critical value(133 ng/mL), the survival time of the patients was significantly shortened(P<0.05). Patients with YKL-40 above the threshold combined with chronic obstructive pulmonary disease(COPD) had significantly shorter survival(P<0.05). Conclusion YKL-40 level can be used as an indicator for the diagnosis of lung cancer, which is correlated to poor prognosis in patients with lung cancer and COPD.